Danno Pharmaceutical-B (06872) signed an exclusive commercial cooperation agreement supplementary agreement with Yuanda Life Sciences

Zhitongcaijing · 2d ago

Zhitong Finance App News, Danno Pharmaceutical-B (06872) issued an announcement. The company has been actively promoting the approval process and corresponding commercialization preparations for the first indication of rifonidazole in China. In order to comply with the relevant review process, ensure that the cooperation arrangement is consistent with the expected commercialization schedule of rifonidazole, and further strengthen the long-term cooperative relationship between the company and Yuanda Life Sciences, the board of directors is pleased to announce that on November 12, 2026, the company and Yuanda Life Science signed a supplementary agreement to the cooperation agreement. Based on this, the two parties agree that Yuanda Life Sciences under the cooperation agreement has the right to unilaterally terminate the relevant period of the cooperation agreement through written notice due to the company's failure to obtain the first indication of rifonidazole in China by the specified date, by December 31, 2026 The date was extended to July 31, 2027.

Other than the relevant adjustments to the final deadline in the supplementary agreement to the cooperation agreement, there are no other substantial changes to the other provisions of the cooperation agreement and continue to be in effect.

The board of directors believes that the conclusion of a supplementary agreement to the cooperation agreement will help to align the cooperation period and related termination arrangements under the cooperation agreement with the listing license and commercialization process of rifonidazole in China, further guarantee that the cooperative relationship that the company has established with Yuanda Life Sciences based on the cooperation agreement conforms to the overall interests of the company and its shareholders.